L
Laurent Mortier
Researcher at university of lille
Publications - 294
Citations - 20214
Laurent Mortier is an academic researcher from university of lille. The author has contributed to research in topics: Medicine & Melanoma. The author has an hindex of 42, co-authored 242 publications receiving 15771 citations. Previous affiliations of Laurent Mortier include Lille University of Science and Technology & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert,Georgina V. Long,Benjamin Brady,Caroline Dutriaux,Michele Maio,Laurent Mortier,Jessica C. Hassel,Piotr Rutkowski,Catriona M. McNeil,Ewa Kalinka-Warzocha,Kerry J. Savage,Micaela Hernberg,Céleste Lebbé,Julie Charles,Catalin Mihalcioiu,Vanna Chiarion-Sileni,Cornelia Mauch,Francesco Cognetti,Ana Arance,Henrik Schmidt,Dirk Schadendorf,Helen Gogas,Lotta Lundgren-Eriksson,Christine Horak,Brian Sharkey,Ian M. Waxman,Victoria Atkinson,Paolo A. Ascierto,Abstr Act +28 more
TL;DR: Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who had metastatic melanoma without a BRAF mutation.
Journal ArticleDOI
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert,Boguslawa Karaszewska,Jacob Schachter,Piotr Rutkowski,Andrzej Mackiewicz,Daniil Stroiakovski,Michael Lichinitser,Reinhard Dummer,Florent Grange,Laurent Mortier,Vanna Chiarion-Sileni,Kamil Drucis,Ivana Krajsová,Axel Hauschild,Paul Lorigan,Pascal Wolter,Georgina V. Long,Keith T. Flaherty,Paul Nathan,Antoni Ribas,Antoni Ribas,Anne-Marie Martin,Peng Sun,Wendy A. Crist,Jeff Legos,Stephen D. Rubin,Shonda M Little,Dirk Schadendorf +27 more
TL;DR: Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity.
Journal ArticleDOI
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey S. Weber,Mario Mandalà,Michele Del Vecchio,Helen Gogas,Ana Arance,C. Lance Cowey,Stéphane Dalle,Michael Schenker,Vanna Chiarion-Sileni,Ivan Marquez-Rodas,Jean-Jacques Grob,Marcus O. Butler,Mark R. Middleton,Michele Maio,Victoria Atkinson,Paola Queirolo,Rene Gonzalez,Ragini R. Kudchadkar,Michael Smylie,Nicolas Meyer,Laurent Mortier,Michael B. Atkins,Georgina V. Long,Shailender Bhatia,Céleste Lebbé,Piotr Rutkowski,Kenji Yokota,Naoya Yamazaki,Tae M. Kim,Veerle de Pril,J Sabater,Anila Qureshi,James Larkin,Paolo A. Ascierto +33 more
TL;DR: Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence‐free survival and a lower rate of grade 3 or 4 adverse events than adjuant therapy with ipilimumab.
Journal ArticleDOI
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Alexander M.M. Eggermont,Vanna Chiarion-Sileni,Jean-Jacques Grob,Reinhard Dummer,Jedd D. Wolchok,Henrik Schmidt,Omid Hamid,Caroline Robert,Paolo A. Ascierto,Jon M. Richards,Céleste Lebbé,Virginia Ferraresi,Michael Smylie,Jeffrey S. Weber,Michele Maio,Lars Bastholt,Laurent Mortier,Luc Thomas,Saad Tahir,Axel Hauschild,Jessica C. Hassel,F. Stephen Hodi,Corina Taitt,Veerle de Pril,Gaetan de Schaetzen,Stefan Suciu,Alessandro Testori +26 more
TL;DR: As adjuvant therapy for high-risk stage III melanoma, ipilimumab at a dose of 10 mg per kilogram resulted in significantly higher rates of recurrence- free survival, overall survival, and distant metastasis-free survival than placebo.
Journal ArticleDOI
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Georgina V. Long,A. Hauschild,M. Santinami,Victoria Atkinson,M. Mandal,Vanna Chiarion-Sileni,James Larkin,Marta Nyakas,Caroline Dutriaux,Andrew Haydon,Caroline Robert,Laurent Mortier,Jacob Schachter,Dirk Schadendorf,Thierry Lesimple,Ruth Plummer,R. Ji,Ping Zhang,Bijoyesh Mookerjee,Jeffrey J. Legos,Richard F. Kefford,Reinhard Dummer,John M. Kirkwood +22 more
TL;DR: Adjuvant use of combination therapy with dabrafenib plus trametinib resulted in a significantly lower risk of recurrence in patients with stage III melanoma with BRAF V600E or V600K mutations than the adjuvantUse of placebo and was not associated with new toxic effects.